Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 15, 2023
Discovery & Translation

Armgo molecule prevents cardiogenic dementia; Ten63’s improved HIV-1 Abs and more

BioCentury’s roundup of translational innovations
BioCentury | Apr 1, 2022
Distillery Therapeutics

Small molecule to control β cell ER stress in diabetes

BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

Emerging science on adhesion molecules, RNA-binding proteins and more at ASH 2018
BioCentury | Feb 27, 2018
Emerging Company Profile

Stressing out cancer

Quentis launches from Glimcher lab with $48M to target ER stress in cancer
BioCentury | Mar 20, 2014
Cover Story

A liver divided

BioCentury | Jul 14, 2011
Targets & Mechanisms

NOGO could go far

BioCentury | Jul 9, 2009
Distillery Therapeutics

Indication: Endocrine disease

Items per page:
1 - 7 of 7
Help Center
Username
Request a Demo
Request Training
Ask a Question